China's health economist outlines pharma strategy: reform, AI, global outreach

Gordon G. Liu, a prominent Chinese health economist, frames China's pharmaceutical ambitions around institutional reform, AI-enabled healthcare, and support for developing countries. The piece is an opinion/interview, not a policy announcement, so concrete changes are uncertain. It signals a strategic direction that could shape China's health-tech and pharma export policies.